BioPharmaTrend
News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech
  • Interviews
  • Business Intelligence
  • Case Studies
Intelligence
  • Business Intelligence
  • Case Studies
  • Lab
  • Membership
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech

  News

Sanofi Licenses BenchSci’s Neurosymbolic AI for Global Preclinical R&D

by Roman Kasianov   •   Oct. 8, 2025

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# AI in Bio   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Sanofi has signed a three-year license agreement with Toronto-based BenchSci to deploy the ASCEND platform across its global preclinical research teams. The partnership marks a move to embed neurosymbolic AI into core R&D operations, offering scientists and contractors at Sanofi access to ASCEND’s structured discovery environment.

#advertisement
AI in Drug Discovery Report 2025

ASCEND is designed as an AI co-pilot for disease biology, combining a biomedical knowledge graph with large language model capabilities. At its core is the Biological Evidence Knowledge Graph (BEKG), which encodes more than 400 million entities and one billion relationships, sourced from full-text articles, experimental figures, reagent metadata, and licensed closed-access journals. The system captures and links experimental context (such as assay types, tissue sources, interventions, and outcomes) to enable traceable, reproducible insights.

BenchSci's "scientist in the loop" framework

According to the release, Sanofi’s license reflects a broader strategy to integrate AI at scale in drug development. With ASCEND, teams will be able to query scientific literature and internal data through a unified reasoning framework, prioritize targets based on biological evidence, and generate structured reports with links to underlying data. According to BenchSci, ASCEND is used at 16 of the top-20 pharma companies and at more than 4,500 research centers worldwide

Case study: From Data to Discovery: How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

The platform supports a range of R&D workflows, including target triage, mechanism exploration, reagent selection, and hypothesis generation. Its AI layer incorporates human-in-the-loop review from a team of over 100 scientists, ensuring consistency and validation across outputs. By aligning data formats and resolving ambiguity, ASCEND aims to reduce duplicated effort and de-risk early-stage decisions.

BenchSci, founded in 2015, has raised over $200 million with backers including Generation Investment Management, iNovia Capital, TCV, F-Prime, Gradient Ventures (Google spin-out), and Golden Ventures. The Sanofi deal adds to its footprint among large pharma clients as it pushes for broader adoption of structured AI infrastructure in discovery R&D.

Just a week ago, BenchSci also announced a collaboration with Thermo Fisher Scientific to co-develop AI tools for preclinical and translational research, pairing ASCEND’s knowledge-graph/LLM stack with Thermo Fisher’s instruments, consumables, and services.

Topic: AI in Bio

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

You may also be interested to read:

BenchSci and Thermo Fisher Collaborate to Develop AI Tools for Preclinical R&D
by Anastasiia Rohozianska
Google-Backed BenchSci Reports New System to Extract Experimental Context From Biomedical Papers Into a Traceable Evidence Graph
by Roman Kasianov
From Data to Discovery: How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning
by BiopharmaTrend

 

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • Business Intelligence
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Lab Access
  • Lab Membership
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.